Indianapolis resident Harry Traugott was an active retiree, participating in community events, driving and even teaching English as a second language at two community centers.

He’d been diagnosed with age-related macular degeneration (AMD), but the disease had not caused significant vision loss. It wasn’t until he had trouble seeing while driving, watching television

Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today (Thursday 11 March) in the European Heart Journal.

A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects. This according to a clinical trial conducted by researchers from the Swedish medical university Karolinska Institutet, amongst other centres, published today in the top-ranking scientific periodical The New England Journal of Medicine.

Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump unwanted or toxic substances away from vulnerable tissues, has announced positive results of a Phase 1a trial for its lead compound, LIM-0705, which has completed its first in man study.

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be available for purchase in Walgreens by May 1, 2010. Walgreens is considered one of the nation’s largest pharmacy chains with 7,162 drugstores located throughout the United States.

Sciele Pharma, Inc., a Shionogi company, today announced the U.S. availability of Adrenaclick™, a single-dose, epinephrine auto-injector for the emergency treatment for severe allergic reactions (Type I) such as anaphylaxis.

Recognizing that salt consumption has long been a concern in matters of health, Boar's Head, one of the nation's leading manufacturers of deli meats and cheeses, reaffirms its commitment to wellness with a campaign that encourages salt sensible food choices. "Launch Your Assault on Salt," offers consumers who have concerns about their salt intake with advice about food options that fit their needs and shows them how, when managed wisely, it can be part of a healthy diet.

Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.

SpectraCell Laboratories announced today that it has agreed with Aetna Health, one of the nation's largest health insurers, to become a contracted in-network provider. The contract provides coverage by Aetna of SpectraCell's micronutrient testing, as well as other advanced tests offered by the company.